 HONG KONG, SHANGHAI, China, SAN DIEGO FLORHAM PARK, N.J., Jan. 10, 2021 GLOBE NEWSWIRE -- Hutchison China MediTech Limited Chi-Med NasdaqAIM: HCM and Inmagene Biopharmaceuticals Inmagene today announce a strategic partnership to further develop four novel preclinical drug candidates discovered by Chi-Med for the potential treatment of multiple immunological diseases. Funded by Inmagene, the companies will work together to move the drug candidates towards investigational new drug IND submission. If successful, Inmagene will then move the drug candidates through global clinical development. 